Zelboraf (vemurafenib) — Medica
Differentiated thyroid carcinoma (radioiodine-refractory)
Initial criteria
- age ≥ 18 years
- differentiated thyroid carcinoma (papillary, follicular, or oncocytic/Hürthle cell subtype)
- disease is refractory to radioactive iodine therapy
- BRAF mutation-positive disease
Approval duration
1 year